US Heart & Vascular (USHV), a leading national cardiovascular physician practice management organization, today announced a strategic collaboration with FillPoint Health, a Lyceum Company and URAC/ACHC-accredited Specialty Pharmacy and Management Services Organization (MSO), and Corstasis Therapeutics to improve access, adherence, and patient outcomes in the management of heart failure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218942256/en/

Under this collaboration, FillPoint Health will serve as the preferred specialty pharmacy and distribution partner for Enbumyst™ (Corstasis Therapeutics' lead product) within USHV’s expanding network of cardiovascular clinics across the United States. The partnership is designed to streamline the delivery of Corstasis’ innovative nasal formulation of bumetanide—offering a nasal administration option for adult patients who experience swelling caused by too much fluid in the body (edema) from congestive heart failure, liver disease and kidney disease, including a kidney problem called nephrotic syndrome.

“Expanding patient access to innovative therapies is central to USHV’s mission and to how we support our physicians,” said Emily Rash, Chief Operating Officer, US Heart & Vascular. “This collaboration strengthens the care pathway for heart failure patients by removing barriers, accelerating time-to-therapy, and equipping our practice-partners with tools that enhance adherence and outcomes. It’s the kind of partnership that enables our teams to deliver better care between appointments and across the entire patient journey.”

The partnership integrates FillPoint Health’s physician-dispense mode with RxNexus’ digital access platform and nationwide specialty pharmacy infrastructure to enable compliant, real-time coordination between providers, payers, and patients. This model supports accelerated time-to-therapy, improved adherence, and actionable data visibility across the treatment continuum.

“Our collaboration with USHV and Corstasis exemplifies FillPoint Health’s mission to bring innovative specialty therapies directly to the point of care,” said Michael Baldzicki, Chief Revenue Officer of FillPoint Health, a Lyceum Company. “Through our integrated pharmacy, technology, and physician-dispense network, we’re creating a frictionless model for heart failure patients to access Enbumyst^TM quickly, conveniently, and compliantly.”

“We’re excited to partner with USHV and FillPoint Health to deliver Enbumyst™ to patients who can benefit from our novel nasal spray formulation,” added Ben Esque, CEO, Corstasis Therapeutics. “This partnership allows Enbumyst^TM to reach patients when they need alternative diuretic options, supporting cardiologists and clinic teams with streamlined access pathways and practical operational tools for integrating Enbumyst^TM into appropriate patient care.”

The collaboration reflects a shared commitment among the three organizations to advance cardiovascular care, reduce access barriers, and strengthen data connectivity between manufacturers, providers, and pharmacies. The initial rollout will begin within select USHV-affiliated cardiology clinics, with plans for nationwide expansion in 2026.

About US Heart & Vascular

US Heart & Vascular (USHV) is a physician-led, national cardiovascular management organization dedicated to transforming heart and vascular care delivery. Through strategic partnerships with leading cardiovascular practices, USHV supports operational excellence, innovation, and patient-centered care across its expanding national footprint.

Learn more at www.usheartandvascular.com.

About FillPoint Health, A Lyceum Company

FillPoint Health is a URAC- and ACHC-accredited Specialty Pharmacy and Management Services Organization (MSO) that partners with manufacturers, provider networks, and payers to streamline specialty therapy access. Through its ecosystem—including NewPoint-Rx (physician-dispense platform) and RxNexus (digital patient-access technology)—FillPoint Health enables compliant, FMV-based specialty workflows designed to accelerate time-to-therapy and improve patient outcomes.

Learn more at www.fillpointhealth.com.

About Corstasis Therapeutics

Corstasis Therapeutics is a biopharmaceutical company focused on developing and commercializing novel therapies to address unmet needs in cardiovascular and renal disease. Its lead product, Enbumyst™ (bumetanide nasal spray), represents an innovative alternative for managing edema associated with fluid overload in patients with heart failure.

Learn more at www.corstasis.com.

INDICATION

ENBUMYST is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including nephrotic syndrome in adults.

IMPORTANT SAFETY INFORMATION

ENBUMYST is contraindicated in patients with anuria, are in hepatic coma, and have a history of hypersensitivity to bumetanide.

ENBUMYST is a diuretic that may cause fluid, electrolyte, and metabolic abnormalities. Excessive fluid loss can lead to dehydration, decreased blood volume, and increased risk of blood clots. Abnormalities may include changes in blood electrolytes, nitrogen, glucose, and uric acid. The chance of getting these abnormalities is higher in people who are elderly, use higher doses, or who do not get enough electrolytes by mouth.

If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, discontinue bumetanide.

Although unlikely at the recommended doses, the potential for ototoxicity must be considered a risk of intravenous therapy, at high doses, repeated frequently in the face of renal excretory function impairment.

Bumetanide can cause dehydration and worsening kidney function; discontinue if azotemia or oliguria increase.

Avoid use in patients with significant nasal mucosal or structural abnormalities, such as acute episodes of rhinitis or congestion due to any cause.

Advise lactating women treated with ENBUMYST to monitor their infants for excessive urine output, dehydration, and lethargy.

Most common adverse reactions are hypovolemia, headache, muscle cramps, dizziness, hypotension, nausea and encephalopathy (in patients with pre-existing liver disease).

These are not all of the possible side effects of ENBUMYST. To report suspected adverse reactions, contact Corstasis Therapeutics at 1-877-300-5339 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the full Prescribing Information for ENBUMYST.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251218942256/en/

"This collaboration strengthens the care pathway for heart failure patients by removing barriers, accelerating time-to-therapy, and equipping our practice-partners with tools that enhance adherence and outcomes." - Emily Rash, COO of USHV